Dan Schell

Forget More Clinical Tech, We Need More Adoption At SCOPE Summit, Craig Lipset shared a blunt assessment of clinical trial innovation: the tools exist, regulators are engaged, and digital approaches offer clear quality advantages — yet adoption remains the industry’s biggest hurdle. Lipset argues progress will depend less on new technology and more on scaling what already works.

By Dan Schell, Chief Editor, Clinical Leader Paul Ivsin You know the type. The panelist who shows up at every conference with a polished deck, a collection of buzzwords, and just enough confidence to convince you they’ve solved patient recruitment once and for all. Then there’s Paul Ivsin. I’ve crossed paths with Paul enough to know that conversations with him rarely stay at surface level for very long. He’s quiet, analytical, and about as far from a “conference personality” as you can get.

The Patient-Centered Trial Paradigm For Knee Osteoarthritis Although PROs can complicate a trial design, they're essential to reflecting a patient’s true knee OA experience and producing meaningful evidence, explains Katie Mowry, Ph.D., VP of R&D at Organogensis. When Participants Need Help, Someone's Got To Respond Support for clinical trial participants helps you ensure requests are handled clearly and in line with study guidelines by managing travel, reimbursements, and logistics.